We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Axcella (AXLA) Up on Patent Grant for Long Covid Fatigue Drug
Read MoreHide Full Article
Axcella Therapeutics secured a methods-of-use patent from the U.S. Patent and Trademark Office for its lead pipeline candidate, AXA1125. The patent has been granted to AXA1125 for treating patients having fatigue associated with post-acute sequelae of Covid-19 or Long Covid. The patent was issued to Axcella on Aug 29, 2023 and is scheduled to expire in 2042.
AXA1125 is AXLA’s novel therapeutic composition, which is being developed using the company’s proprietary endogenous metabolic modulators (EMMs) to simultaneously support metabolic, inflammatory and fibrotic pathways associated with fatigue caused by Long Covid. We would like to remind the investors that AXA1125 has several other patents already granted with claims covering methods of use and compositions.
The previously granted patents for AXA1125 are anticipated to expire in 2037.
Shares of the company skyrocketed 298.9% during the trading session on Tuesday, followed by a 13.3% rise in stock price during the after-market hours. Year to date, shares of Axcella have shot up 37.4% against the industry’s 12.8% fall.
Image Source: Zacks Investment Research
Axcella’s EMMs comprise a range of meticulously engineered molecules, including amino acids that fundamentally impact and regulate human metabolism. Management believes that its EMMs are different from current targeted interventions that used to address dysregulated metabolism and have the potential to disrupt the market. The latest patent strengthens AXLA’s intellectual property rights to its novel composition of amino acids in AXA1125, while reaffirming its effectiveness in the treatment of Long Covid fatigue.
Notably, AXA1125 for Long Covid fatigue is currently Axcella’s only ongoing clinical pipeline program. The company had previously terminated the development of another EMM therapeutic candidate, AXA1665, to treat liver-related metabolic disease as well as mid-stage studies on AXA1125 to treat nonalcoholic steatohepatitis in adult and pediatric patients.
The above decisions were taken as part of the company’s restructuring and reprioritization efforts to streamline its focus on the development of AXA1125 to treat Long Covid fatigue. Earlier this year, the company reached an agreement with the FDA as well as U.K.’s regulatory authority regarding a registrational phase IIb/III study of AXA1125 in Long Covid fatigue.
The agreement was based on clinically and statistically significant improvement in mental and physical fatigue scores compared with placebo subjects in the completed phase IIa study of AXA1125.
Some other top-ranked stocks in the pharma/biotech sector worth mentioning are J&J (JNJ - Free Report) , Corcept Therapeutics (CORT - Free Report) and Dynavax Technologies (DVAX - Free Report) , each carrying a Zacks Rank #2 at present.
In the past 30 days, the Zacks Consensus Estimate for J&J’s 2023 earnings per share has increased from $10.73 to $10.75. During the same period, the estimate for JNJ’s 2024 earnings per share has increased from $11.28 to $11.30. Year to date, shares of JNJ have lost 7%.
JNJ beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 5.58%.
In the past 30 days, the Zacks Consensus Estimate for Corcept’s 2023 earnings per share has gone up from 62 cents to 78 cents. The estimate for Corcept’s 2024 earnings per share has also improved from 61 cents to 83 cents. Year to date, shares of CORT have climbed 61.6%.
CORT’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 6.99%.
In the past 30 days, the Zacks Consensus Estimate for Dynavax’s 2023 loss per share has narrowed from 51 cents to 24 cents. The estimate for Dynavax’s 2024 earnings per share is currently pegged at 2 cents. Year to date, shares of DVAX have risen by 36.9%.
DVAX’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 25.78%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Axcella (AXLA) Up on Patent Grant for Long Covid Fatigue Drug
Axcella Therapeutics secured a methods-of-use patent from the U.S. Patent and Trademark Office for its lead pipeline candidate, AXA1125. The patent has been granted to AXA1125 for treating patients having fatigue associated with post-acute sequelae of Covid-19 or Long Covid. The patent was issued to Axcella on Aug 29, 2023 and is scheduled to expire in 2042.
AXA1125 is AXLA’s novel therapeutic composition, which is being developed using the company’s proprietary endogenous metabolic modulators (EMMs) to simultaneously support metabolic, inflammatory and fibrotic pathways associated with fatigue caused by Long Covid. We would like to remind the investors that AXA1125 has several other patents already granted with claims covering methods of use and compositions.
The previously granted patents for AXA1125 are anticipated to expire in 2037.
Shares of the company skyrocketed 298.9% during the trading session on Tuesday, followed by a 13.3% rise in stock price during the after-market hours. Year to date, shares of Axcella have shot up 37.4% against the industry’s 12.8% fall.
Image Source: Zacks Investment Research
Axcella’s EMMs comprise a range of meticulously engineered molecules, including amino acids that fundamentally impact and regulate human metabolism. Management believes that its EMMs are different from current targeted interventions that used to address dysregulated metabolism and have the potential to disrupt the market. The latest patent strengthens AXLA’s intellectual property rights to its novel composition of amino acids in AXA1125, while reaffirming its effectiveness in the treatment of Long Covid fatigue.
Notably, AXA1125 for Long Covid fatigue is currently Axcella’s only ongoing clinical pipeline program. The company had previously terminated the development of another EMM therapeutic candidate, AXA1665, to treat liver-related metabolic disease as well as mid-stage studies on AXA1125 to treat nonalcoholic steatohepatitis in adult and pediatric patients.
The above decisions were taken as part of the company’s restructuring and reprioritization efforts to streamline its focus on the development of AXA1125 to treat Long Covid fatigue. Earlier this year, the company reached an agreement with the FDA as well as U.K.’s regulatory authority regarding a registrational phase IIb/III study of AXA1125 in Long Covid fatigue.
The agreement was based on clinically and statistically significant improvement in mental and physical fatigue scores compared with placebo subjects in the completed phase IIa study of AXA1125.
Axcella Health Inc. Price and Consensus
Axcella Health Inc. price-consensus-chart | Axcella Health Inc. Quote
Zacks Rank & Other Stocks to Consider
Axcella currently has a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the pharma/biotech sector worth mentioning are J&J (JNJ - Free Report) , Corcept Therapeutics (CORT - Free Report) and Dynavax Technologies (DVAX - Free Report) , each carrying a Zacks Rank #2 at present.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 30 days, the Zacks Consensus Estimate for J&J’s 2023 earnings per share has increased from $10.73 to $10.75. During the same period, the estimate for JNJ’s 2024 earnings per share has increased from $11.28 to $11.30. Year to date, shares of JNJ have lost 7%.
JNJ beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 5.58%.
In the past 30 days, the Zacks Consensus Estimate for Corcept’s 2023 earnings per share has gone up from 62 cents to 78 cents. The estimate for Corcept’s 2024 earnings per share has also improved from 61 cents to 83 cents. Year to date, shares of CORT have climbed 61.6%.
CORT’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 6.99%.
In the past 30 days, the Zacks Consensus Estimate for Dynavax’s 2023 loss per share has narrowed from 51 cents to 24 cents. The estimate for Dynavax’s 2024 earnings per share is currently pegged at 2 cents. Year to date, shares of DVAX have risen by 36.9%.
DVAX’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 25.78%.